Squarepoint Ops LLC Buys Shares of 16,764 Sera Prognostics, Inc. (NASDAQ:SERA)

Squarepoint Ops LLC purchased a new stake in Sera Prognostics, Inc. (NASDAQ:SERA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 16,764 shares of the company’s stock, valued at approximately $136,000.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Sera Prognostics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 599,702 shares of the company’s stock worth $4,883,000 after buying an additional 12,865 shares during the period. Captrust Financial Advisors lifted its position in shares of Sera Prognostics by 2.2% during the fourth quarter. Captrust Financial Advisors now owns 487,894 shares of the company’s stock worth $3,971,000 after purchasing an additional 10,673 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Sera Prognostics by 11.8% in the fourth quarter. Northern Trust Corp now owns 272,860 shares of the company’s stock valued at $2,221,000 after purchasing an additional 28,863 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Sera Prognostics by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company’s stock valued at $661,000 after purchasing an additional 4,115 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Sera Prognostics during the 4th quarter worth approximately $576,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Stock Down 3.2%

Shares of SERA opened at $1.50 on Tuesday. The company has a market capitalization of $56.51 million, a price-to-earnings ratio of -1.52 and a beta of 0.71. Sera Prognostics, Inc. has a 52-week low of $1.37 and a 52-week high of $9.13. The stock has a 50 day moving average price of $2.60 and a 200 day moving average price of $4.73.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, equities analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered Sera Prognostics from a “hold” rating to a “sell” rating in a report on Friday.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.